Zobrazeno 1 - 10
of 81
pro vyhledávání: '"K. J. Pasi"'
Autor:
K. J. Pasi, C Sussebach, Pratima Chowdary, Z Qiu, Margaret V. Ragni, Claude Negrier, S. Andersson, Inga Hegemann, S Poloskey, Pencho Georgiev, B. Mei, Steven W. Pipe, S Kichou, T Lissitchkov
Publikováno v:
65th Annual Meeting of the Society of Thrombosis and Haemostasis Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ae5618d0d5308ed25ee8b7eb8c046b8
https://doi.org/10.1055/s-0041-1728092
https://doi.org/10.1055/s-0041-1728092
PK-guided personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in adults with severe haemophilia A
Autor:
Pencho Georgiev, Larisa Belyanskaya, Toshko Lissitchkov, Olaf Walter, Sigurd Knaub, Jerzy Windyga, Andreas Tiede, L. Rusen, K. J. Pasi, Liana Gercheva, Johann Bichler, László Nemes, Robert Klamroth
Publikováno v:
Haemophilia. 23:697-704
Introduction Nuwiq® (human-cl rhFVIII) is a 4th generation recombinant human FVIII, without chemical modification or protein fusion, produced in a human cell-line. Aims/Methods This study (NuPreviq) was a prospective, open-label, multicentre, phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05279f37fd6d8c2674bb2be7063a7a75
https://doi.org/10.1111/hae.13251
https://doi.org/10.1111/hae.13251
Autor:
Alejandra Ramirez-Santiago, K. J. Pasi, Roshni Kulkarni, Johannes Oldenburg, D. J. Perry, Baisong Mei, Margaret V. Ragni, Tadashi Matsushita, Amy D. Shapiro, Carolyn M. Bennett, Krista Fischer, Beatrice Nolan, Chris Barnes, Johnny Mahlangu, Huixing Yuan, Glenn F. Pierce, Margareth C. Ozelo, Ross I. Baker, G. Allen
Publikováno v:
Thrombosis and Haemostasis. 117:508-518
SummaryThe safety, efficacy, and prolonged half-life of recombinant factor IX Fc fusion protein (rFIXFc) were demonstrated in the Phase 3 B-LONG (adults/adolescents ≥12 years) and Kids B-LONG (children Supplementary Material to this article is avai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c10b67eef88edca7ecd10233367cd81
https://doi.org/10.1160/th16-05-0398
https://doi.org/10.1160/th16-05-0398
Autor:
B. Mei, Claude Negrier, Pencho Georgiev, A.N.L. Prezotti, S. Andersson, K. J. Pasi, K. Salim, Toshko Lissitchkov, Margaret V. Ragni
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 74-75 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5e6309797aa22967888893da44278b
https://doi.org/10.1016/j.htct.2020.10.124
https://doi.org/10.1016/j.htct.2020.10.124
Publikováno v:
Journal of Thrombosis and Haemostasis. 14:2141-2147
Essentials No randomized trials have compared long-acting factor VIII (FVIII) with currently used products. A comparison was undertaken using a decision model to predict FVIII use and number of bleeds. In the base case, longer acting FVIII reduced fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381c8dcfe928fc28ea89d9d1c4f31af3
https://doi.org/10.1111/jth.13440
https://doi.org/10.1111/jth.13440
Autor:
Alun Thomas, Elizabeth Chalmers, Savita Rangarajan, Mary Mathias, James S. O’Donnell, K. J. Pasi, Peter William Collins, Pratima Chowdary, David Keeling
Publikováno v:
Haemophilia. 22:487-498
Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f320e88be31270a3920a453fc7b64a
https://doi.org/10.1111/hae.13013
https://doi.org/10.1111/hae.13013
Autor:
E. Symington, M. Li, N. Mitchell, G.F. Pierce, W.Y. Wong, B. Madan, C.B. Russell, S. Rangarajan, Margareth C. Ozelo, B. Kim, W. Lester, M. Laffan, K. J. Pasi
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 60-(2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae6038e7f33aad25e7c08c2b84a0feb1
https://doi.org/10.1016/j.htct.2020.10.099
https://doi.org/10.1016/j.htct.2020.10.099
Autor:
K. J. Pasi, Johnny Mahlangu, Barbara A. Konkle, Simon A Brown, H. Hanabusa, X Li, Savita Rangarajan, G. Allen, Ingrid Pabinger, Lynda M. Cristiano, Beatrice Nolan, D. J. Perry, R. Liesner, Glenn F. Pierce, Guy Young, Shannon Jackson
Publikováno v:
Haemophilia. 22:72-80
Introduction The safety, efficacy and prolonged half-life of recombinant factor VIII Fc fusion protein (rFVIIIFc) in previously treated patients with severe haemophilia A was demonstrated in the phase 3 A-LONG and Kids A-LONG studies. Here, we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e85ad2a1ea01d5a1dcd57867838c2a23
https://doi.org/10.1111/hae.12766
https://doi.org/10.1111/hae.12766
Publikováno v:
Haemophilia. 21:490-495
Introduction Factor XI (FXI) deficiency is the commonest of the rare bleeding disorders, affecting 2079 individuals in the United Kingdom. Treatment options for bleeding or surgery include antifibrinolytics, fresh frozen plasma or plasma-derived (pd)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a3b016989aed031b5f8e5157e1c8b50
https://doi.org/10.1111/hae.12682
https://doi.org/10.1111/hae.12682
Autor:
Savita Rangarajan, Daniel P. Hart, B. Palmer, Sean Platton, J. C. Maloney, P. Batty, Gary W. Moore, K. J. Pasi, Louise Bowles
Publikováno v:
Thrombosis and Haemostasis. 114:804-811
SummaryAntibody formation to factor VIII (FVIII) remains the greatest clinical and diagnostic challenge to the haemophilia-treating physician. Current guidance for testing for inhibitory FVIII antibodies (inhibitors) recommends the functional Nijmege
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85383b15f8cc17a3c9a590519ae072b6
https://doi.org/10.1160/th14-12-1062
https://doi.org/10.1160/th14-12-1062